



\*\*REPRESENTATIVE DATA SHEET\*\*

## Matched-Pair Antibody Set for ELISA of Human TAFI antigen (Thrombin Activatable Fibrinolysis Inhibitor)

Sufficient reagent for 4 x 96 well plates

**Product #:** TAFI-EIA  
**Lot #:** S A M P L E  
**Expiry Date:** S A M P L E

Store at 2–8°C

For Research Use Only  
Not for use in diagnostic procedures.

### Description of TAFI (proCPU)

TAFI (Thrombin Activatable Fibrinolysis Inhibitor), also referred to as plasma procarboxypeptidase-B, procarboxypeptidase-U and R, circulates in plasma as a zymogen with a mass of 58,000 daltons (1-6). Proteolytic activation of TAFI yields an N-terminally derived activation peptide and the C-terminal portion corresponding to the metalloprotease, activated TAFI (TAFIa). TAFIa exhibits exopeptidase activity with carboxypeptidase B-like substrate specificity capable of catalyzing the hydrolysis of C-terminal lysine and arginine residues. Cleavage of these residues on fibrin by TAFIa attenuates clot lysis by inhibiting the formation of the ternary activation complex comprising fibrin cofactor, tPA and plasminogen, thereby inhibiting plasmin generation. Although TAFI can be activated by various proteases including thrombin and plasmin, the physiological activator is proposed to be the complex thrombin-thrombomodulin since the rate of activation is stimulated 1250-fold compared to thrombin alone (4). However, the rate of TAFI activation is highly dependent upon its plasma concentration. Since TAFIa apparently plays a key role in connecting coagulation and fibrinolysis and significantly increases clot stability, determination of plasma concentration of TAFI is likely crucial to assess its subsequent potential antifibrinolytic effects.

### Principle of Sandwich-style ELISA

Affinity-purified antibody to TAFI is coated onto the wells of a microtitre plate. Any remaining binding sites on the plastic wells are blocked with an excess of bovine serum albumin. The plates are washed and plasma or other fluids containing TAFI are applied. The coated antibody will capture the TAFI in the sample. After washing the plate to remove unbound material, a peroxidase conjugated second antibody to TAFI is added to the plate to bind to the captured TAFI. After washing the plate to remove unbound conjugated antibody, the peroxidase activity is expressed by incubation with o-phenylenediamine (OPD). After a fixed development time the reaction is quenched with the addition of H<sub>2</sub>SO<sub>4</sub> and the colour produced is quantified using a microplate reader. The colour generated is proportional to the concentration of TAFI present in the sample.

Document OPI0093, rev 1

### Supplied Materials:

- 1. Capture Antibody (TAFI-EIA-C):** One yellow-capped vial containing 0.4 ml of polyclonal affinity-purified anti-TAFI antibody for coating plates.
- 2. Detecting Antibody (TAFI-EIA-D):** Four neutral-capped tubes each containing 10 ml of pre-diluted peroxidase conjugated polyclonal anti-TAFI antibody for detection of captured TAFI.

Store antibodies at 2-8°C

### Materials Required but not Provided:

- 1. Coating Buffer:** 50 mM Carbonate  
1.59g of Na<sub>2</sub>CO<sub>3</sub> and 2.93g of NaHCO<sub>3</sub> up to 1 litre. Adjust pH to 9.6. Store at 2-8°C up to 1 month.
- 2. PBS:** (base for wash buffer and blocking buffer)  
8.0g NaCl, 1.15g Na<sub>2</sub>HPO<sub>4</sub>, 0.2g KH<sub>2</sub>PO<sub>4</sub> and 0.2g KCl, up to 1 litre. Adjust pH to 7.4, if necessary. Store up to 1 month at 2-8°C, discard if there is evidence of microbial growth.
- 3. Wash Buffer:** PBS-Tween (0.1%,v/v)  
To 1 litre of PBS add 1.0 ml of Tween-20.  
Check that the pH is 7.4. Store at 2-8°C up to 1 week.
- 4. Blocking Buffer:** PBS-BSA (1%, w/v)  
Dissolve 2.5 g of Bovine Serum Albumin (Sigma-RIA grade) in 200 ml of PBS. Adjust pH to 7.4, if required, then make up to 250 ml with PBS. Aliquot and store frozen at -20°C.
- 5. Sample Diluent:** HBS-BSA-T20  
5.95g HEPES (free acid), 1.46 g NaCl, 2.5 g Bovine Serum Albumin (Sigma, RIA grade) dissolved in 200 ml H<sub>2</sub>O. Add 0.25 ml of Tween-20, check and adjust pH to 7.2 with NaOH, then make up to a final volume of 250 ml with H<sub>2</sub>O. Aliquot and store frozen at -20°C.
- 6. Substrate Buffer:** Citrate-Phosphate buffer pH 5.0  
2.6g Citric acid and 6.9g Na<sub>2</sub>HPO<sub>4</sub> up to a final volume of 500 ml with purified H<sub>2</sub>O. Store at 2-8°C up to 1 month.
- 7. OPD Substrate:** (o-Phenylenediamine.2HCl) TOXIC!  
(5mg tablets: Sigma # P-6912). Make up immediately before use. Dissolve 5mg OPD in 12 ml substrate buffer then add 12 µl 30% H<sub>2</sub>O<sub>2</sub>. Do not store.
- 8. Stopping Solution:** 2.5 M H<sub>2</sub>SO<sub>4</sub>  
Caution: VERY CORROSIVE! GENERATES HEAT ON DILUTION! Where stock sulphuric acid is 18 Molar, add 13.9 ml to 86 ml H<sub>2</sub>O. Store at room temperature.

### 9. Other:

Microplates, 96-well Immulon 4-HBX (<http://www.labsystems.fi>)  
Microplate washer (optional)  
Microplate reader.

## Assay Procedure:

### 1. Coating of plates:

Dilute the capture antibody 1/100 in coating buffer (preferably in a polypropylene tube) and immediately add 100 µl to every well in the plate. Incubate overnight at 2-8°C.

### 2. Blocking:

Empty contents of plate and add 150 µl of blocking buffer to every well and incubate for 60 minutes @ 22°C.

Wash plate X 3 with wash buffer.

### 3. Samples:

Reference plasma is diluted 1/100 (100%) then serial 1/2's down to 1/3200 (3.13%). Sample plasmas are diluted 1/200, 1/400 & 1/800. All dilutions are made in HBS-BSA-T20 sample diluent. Apply 100 µl/well and incubate plate @ 22°C for 120 minutes.

Wash plate X 3 with wash buffer.

### 4. Detecting Antibody:

Apply the pre-diluted detecting antibody, 100 µl to each well. Incubate plate @ 22°C for 60 minutes.

Wash plate X 3 with wash buffer.

### 5. OPD Substrate:

Apply 100 µl of freshly prepared OPD substrate to every well. Allow colour to develop for 10-15 minutes and then stop colour reaction with the addition of 50 µl/well of 2.5 M H<sub>2</sub>SO<sub>4</sub>. The plate can be read at wavelength of 490 nm.

## Calculation of Results:

The construction of a proper reference curve is of no less importance than any other aspect of the assay. A reference curve should be constructed by plotting the known concentration of standards versus absorbance. This can be done manually using graph paper, or by using curve-fitting computer software. In our experience, the dose response curves of most immunoassays tend to be sigmoid in shape. Although linear regions can be identified within the curve, the best overall fit is often obtained using an algorithm that provides a weighted theoretical model of fit throughout the entire curve, such as a 4-parameter or 5-parameter logistic curve fit<sup>8,9</sup>. In general, the simplest model that defines the concentration-response relationship should be used<sup>9</sup>.

The "back-fit" test is a simple and reliable method to determine if a curve-fitting method is appropriate. In this test, the apparent concentrations for the absorbance values of each standard point are read from the reference curve. The derived values are compared to the assigned values. An appropriate curve fitting method will produce derived values that closely match assigned values throughout the range of the curve, within user-defined limits<sup>6</sup>. The coefficient of determination ( $R^2$ ) is a valuable indicator of the overall fit, but should not be used by itself in the selection of a curve fitting method, as a poor fit in a particular region of the curve may not be evident from this value alone<sup>8,9</sup>.

**In the quality control of this product we have determined that under the conditions described above, a reference curve that is constructed using serial dilutions of normal pooled plasma, will produce a correlation coefficient ( $R^2$ ) of at least 0.980 using a log-log fit, and an  $R^2$  of at least 0.990 using a 4-parameter logistic curve fit algorithm.** However, the performance characteristics of in-house assays developed using this product in other laboratories may vary slightly from ours. Different curve fitting methods may be employed but we recommend that the back-fit test be applied as evidence that the fitting method is appropriate.

## Technical Notes:

- This paired antibody product is intended to facilitate the end user in establishing an in-house immunoassay for research purposes only. It must not be used for diagnostic applications. Assay validation is the responsibility of the end user and should be done according to user-defined protocols<sup>9</sup>.
- Reference calibrators should be of the same matrix and anticoagulant as the samples to be tested (example serum or plasma, citrate or EDTA)
- Do not use samples diluted less than 1/10, as falsely high readings may result.
- The optimal colour development time should be determined empirically as the time required to obtain an absorbance of at least 1.000 at 490 nm for the 100% reference point, not to exceed 20 minutes.
- Rheumatoid factor in samples may interfere in ELISA by binding to the capture and/or detecting antibodies.
- The wells should not be allowed to become dry. Keep plate covered or in a humid chamber during incubations.
- The capture antibody is supplied in a 50% glycerol solution and can be centrifuged briefly in a micro-centrifuge to gather residual reagent from the cap and walls of the tube.

## References:

1. Eaton, D.L., Malloy, B.E., Tsai, S.P., Henzel, W., Drayna, D., Isolation, Molecular Cloning and Partial Characterization of a Novel Carboxypeptidase B from Human Plasma. *J.Biol.Chem.* 266:21833-21838, 1991.
2. Hendriks, D., Scharpe, S., van Sande, M., Lommaert, M.P., Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. *J.Clin.Chem.Clin.BioChem.* 27:277-285, 1989.
3. Campbell, W., Okada, J. An Arginine specific carboxypeptidase generated in blood during coagulation of inflammation which is unrelated to carboxypeptidase N or its subunits. *Biochem.Biophys.Res.Comm.* 162:933-939, 1989.
4. Bajzar, L., Morser, J., Nesheim, M.E. TAFI, or procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. *J.Biol.Chem.* 271:16603-16608, 1996.
5. Mosnier, L.O., von Dem Borne, P.A. Meijers, J.C., Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. *Thromb.Haemost.* 80:829-835, 1998.
6. Juhan-Vague, I., Renucci, J.F., and Grimaux, M., Morange, P.E., Gouvernet, J., Gourmelin, Y., Laessi, M.C. Thrombin Activatable Fibrinolysis Inhibitor Antigen Levels and cardiovascular Risk Factors. *Arter.Thromb.Vascular.Biology.* 20:2156-2161, 2000.
7. Nix, B, Wild D, in Immunoassays, A Practical Approach, editor J.P. Gosling, pp. 239-261, Oxford University Press, 2000.
8. NCCLS. Evaluation of the Linearity of Quantitative Analytical Methods; Proposed Guideline – Second Edition. NCCLS Document EP6-P2 (ISBN 1-56238-446-5, NCCLS, Wayne, Pennsylvania, USA, 2001.
9. FDA Guidance for Industry. Bioanalytical Method Validation; May 2001, available on the internet: [www.fda.gov/cder/guidance/index.htm](http://www.fda.gov/cder/guidance/index.htm)

## Related Products:

Cat #: <b>SATAFI-AP</b>	Sheep anti-human TAFI, affinity purified IgG
Cat #: <b>SATAFI-HRP</b>	Sheep anti-human TAFI, IgG-peroxidase
Cat #: <b>TAFI-AG</b>	<b>VisuLize ELISA KIT</b> for TAFI antigen, 1 x 96 test
Cat #: <b>TAFI-DP</b>	Human plasma deficient in TAFI, immune depleted